Am­gen hands off rights to lep­rosy, tu­ber­cu­lo­sis med picked up as part of $13.4B Ote­zla deal

Am­gen scored a big pick­up with its ac­qui­si­tion of im­munol­o­gy block­buster Ote­zla from Bris­tol My­ers Squibb late last year. But that deal al­so came with a mol­e­cule for tu­ber­cu­lo­sis and lep­rosy with sig­nif­i­cant­ly less com­mer­cial val­ue, and Am­gen is ready to wipe its hands clean.

As part of the $13.4 bil­lion deal, Am­gen took over what be­came AMG 634 — a phos­pho­di­esterase type 4 in­hibitor cur­rent­ly in Phase II tri­als that is be­ing in­ves­ti­gat­ed for the treat­ment of both tu­ber­cu­lo­sis and ery­the­ma no­dosum lep­ro­sum, a com­pli­ca­tion from lep­rosy.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.